Table 4.
Survival outcomes according to the sequential use of risk scores during repeated TACE rounds
| Risk scores | Median survival (95% CI) | Survival rate | Cox regression | |||
|---|---|---|---|---|---|---|
| 1-year | 3-years | 5-years | HR (95% CI) | P value* | ||
| mHAP-II (n = 619) | ||||||
| A-B at the first TACE (n = 283) | ||||||
| No second TACE (n = 55) | – | – | – | – | – | – |
| A-B at the second TACE (n = 185) | 40.6 (36.6–44.6) | 89.6% | 58.6% | 35.5% | 1 | – |
| C-D at the second TACE (n = 43) | 19.6 (16.6–22.6) | 66.8% | 25.4% | 16.4% | 2.15 (1.48–3.12) | <0.001 |
| C-D at the first TACE (n = 336) | 21.5 (18.5–24.5) | 65.7% | 31.3% | 16.8% | 2.31 (1.85–2.87) | <0.001 |
| mHAP (n = 619) | ||||||
| A-B at the first TACE (n = 519) | ||||||
| No second TACE (n = 82) | – | – | – | – | – | – |
| A-B at the second TACE (n = 412) | 31.2 (27.5–34.9) | 81.2% | 44.6% | 26.2% | 1 | |
| C-D at the second TACE (n = 25) | 16.9 (2.9–30.9) | 56.0% | 16.0% | 8.0% | 2.28 (1.49–3.48) | <0.001 |
| C-D at the first TACE (n = 100) | 10.2 (8.3–12.1) | 40.2% | 15.5% | 9.3% | 2.91 (2.29–3.69) | <0.001 |
| HAP (n = 619) | ||||||
| A-B at the first TACE (n = 394) | ||||||
| No second TACE (n = 71) | – | – | – | – | – | – |
| A-B at the second TACE (n = 278) | 35.8 (31.3–40.3) | 84.6% | 49.6% | 30.0% | 1 | |
| C-D at the second TACE (n = 45) | 21.0 (15.0–27.0) | 70.6% | 23.9% | 12.1% | 1.84 (1.30–2.62) | 0.001 |
| C-D at the first TACE (n = 225) | 48.6 (14.2–23.0) | 60.2% | 27.4% | 15.7% | 2.17 (1.77–2.66) | <0.001 |
P value* indicate the comparison with A-B of risk scores at the first TACE
TACE trans-arterial chemoembolization, CI confidence interval, HR hazard ratio, mHAP modified hepatoma arterial-embolization prognostic